Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Genetic Testing

NEW YORK – Twist Bioscience and Centogene announced on Wednesday a collaboration to develop and commercialize sequencing assay kits for rare disease genetic testing.

The assays will combine Centogene's experience in rare disease diagnostics with Twist's target enrichment capabilities for next-generation sequencing library preparation. The partners will design multiple tests and will attempt to make genetic testing more accessible to patients.

Financial and other details were not disclosed.

"Not only will this help to provide patients with quicker and more comprehensive answers today, but it will generate insights to advance the precision medicine of tomorrow," Centogene CEO Andrin Oswald said in a statement. 

In July, Twist acquired NGS library prep company iGeomix, and in March, it partnered with Watchmaker Genomics on high-throughput NGS applications.

In June, Centogene partnered with Alector on a study to identify patients with frontotemporal dementia who have certain genetic mutations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.